Job title: VP, Cell Biology and Immunology
25 years of experience working in biotech, coordinating efforts focused on the discovery and development of novel biologic-based therapies. At MacroGenics, leads a research group dedicated to the discovery, preclinical development and clinical translational biology of antibody-based therapeutics including Fc-optimized mAbs and bispecifics for cancer or autoimmune disease through harnessing of the host immune system. Began biotechnology career at HGS, where directed genomic-based target discovery programs and the preclinical development of various protein and mAb-based therapeutics. Notably these efforts led to the discovery of BLyS as a B-cell survival factor providing the basis for the development of Benlysta for the treatment for lupus. Obtained PhD from University of Glasgow and performed post-doctoral work at the Roche Institute of Molecular Biology; co-authored over 70 peer-reviewed manuscripts and 40 issued US patents.
Improving CD3 Bi-Specific Therapeutic Responses through Combination Regimens & Molecular Design 12:00 pm
Enhancing CD3 bispecific molecule activity through combination with checkpoint inhibition or co-stimulation Segregating cytolytic activity from cytokine response through molecular design Maximizing CD3 bispecific exposure and durable pharmacodynamic activity with enhanced safety in non-human primatesRead more
day: Day Two